losartan has been researched along with Hypertension, Renal in 90 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 9.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "Losartan may be introduced within 2-7 days of mild stroke in hypertensive patients in whom significant carotid occlusive disease has been excluded without affecting global or regional CBF, or affecting GFR." | 9.11 | The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. ( Bolster, A; Hilditch, TE; Lees, KR; Nazir, FS; Overell, JR; Reid, JL, 2004) |
| "We conclude that pravastatin administration is associated with improved proteinuria probably by inhibiting urine ET-1 levels in patients with losartan-based treatment." | 9.11 | Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. ( Chang, NC; Lee, TM; Lin, MS; Tsai, CH, 2005) |
| "To report a case of angioedema associated with the angiotensin II receptor antagonist losartan." | 7.70 | Angioedema due to losartan. ( Cha, YJ; Pearson, VE, 1999) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 5.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "Losartan may be introduced within 2-7 days of mild stroke in hypertensive patients in whom significant carotid occlusive disease has been excluded without affecting global or regional CBF, or affecting GFR." | 5.11 | The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. ( Bolster, A; Hilditch, TE; Lees, KR; Nazir, FS; Overell, JR; Reid, JL, 2004) |
| "Absence of BP response to losartan does not preclude a reduction in albuminuria, and optimal reduction of albuminuria may require titration beyond the predefined BP target." | 5.11 | Renoprotection with and without blood pressure reduction. ( Andersen, S; de Zeeuw, D; Laverman, GD; Navis, G; Parving, HH; Rossing, P, 2005) |
| "We conclude that pravastatin administration is associated with improved proteinuria probably by inhibiting urine ET-1 levels in patients with losartan-based treatment." | 5.11 | Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. ( Chang, NC; Lee, TM; Lin, MS; Tsai, CH, 2005) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "Effects of losartan and amlodipine on blood pressure and albuminuria were compared in a randomized, double-blind, parallel trial involving 48 patients with essential hypertension (sitting diastolic blood pressure between 95 to 115 mm Hg) and impaired renal function (creatinine clearance of 30 to 60 ml/min/1." | 5.08 | Comparison of losartan and amlodipine in renally impaired hypertensive patients. ( Aranda, P; Casado, S; Fernández-Andrade, C; Guerra, L; Iversen, B; Russo, D; Zucchelli, P, 1998) |
| " Hypertension-induced marked elevation of renal malondialdehyde (MDA) and nitrite levels and reduction of reduced glutathione (GSH) level were inhibited by EGb761." | 3.88 | Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats. ( Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM, 2018) |
| " We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury." | 3.74 | Overexpression of angiotensinogen increases tubular apoptosis in diabetes. ( Brezniceanu, ML; Chan, JS; Chénier, I; Filep, JG; Ingelfinger, JR; Liu, F; Sachetelli, S; Wei, CC; Zhang, SL, 2008) |
| "The potential antithrombotic action of losartan, an AT1 receptor antagonist, administered to two-kidney, one-clip rats (2K1C) in an experimental model of venous thrombosis was evaluated." | 3.70 | Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. ( Buczko, W; Chabielska, E; Pawlak, R; Rółkowski, R; Wollny, T, 1999) |
| "To report a case of angioedema associated with the angiotensin II receptor antagonist losartan." | 3.70 | Angioedema due to losartan. ( Cha, YJ; Pearson, VE, 1999) |
| "To separate the role of ANG II from pressure in hypertrophy of the vascular wall in one-kidney, one-clip (1K1C) hypertension, experimental and sham-operated rats were given the AT(1)-receptor antagonist losartan (20 mg x kg(-1) x day(-1)) or tap water for 14 days." | 3.70 | AT(1) receptor inhibition does not reduce arterial wall hypertrophy or PDGF-A expression in renal hypertension. ( Dobrian, AD; Parker, SB; Prewitt, RL; Wade, SS, 2000) |
| " Angiotensin-converting enzyme (ACE) inhibitors appear to be the drugs of choice since they not only lower blood pressure but also reduce some important risk factors that may cause progressive loss of renal function, such as intraglomerular hypertension, angiotensin II (Ang II)-induced glomerular growth, proteinuria and hyperlipidemia." | 3.69 | Losartan in patients with renal insufficiency. ( de Jong, PE; de Zeeuw, D; Gansevoort, RT, 1995) |
| " Patients received open-label treatment with a conventional dosage of benazepril (10 mg/d), individual uptitration of benazepril (median 20 mg/d; range 10 to 40), a conventional dosage of losartan (50 mg/d), or individual uptitration of losartan (median 100 mg/d; range 50 to 200)." | 2.73 | Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. ( Chen, PY; Guo, ZJ; Hou, FF; Jiang, JP; Liang, M; Xie, D; Zhang, WR; Zhang, X, 2007) |
| "Data on the duration of ESRD were used to estimate the economic benefits of slowing the progression of nephropathy." | 2.71 | Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. ( Alexander, CM; Brenner, BM; Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2003) |
| "Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2." | 2.71 | Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for ( Hayashi, M; Ideura, T; Iino, Y; Kawaguchi, Y; Kawamura, T; Kitajima, T; Koyama, A; Kuwahara, M; Shiigai, T; Sugisaki, T; Suzuki, H; Tomino, Y; Uchida, S; Umemura, S; Yamada, K; Yamazaki, T, 2003) |
| "In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of renal function." | 2.71 | Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| "Data on the duration of ESRD for the Asian subgroup of patients enrolled in RENAAL were used to estimate the economic benefits of slowing the progression of nephropathy." | 2.71 | Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. ( Burke, TA; Carides, GW; Chan, J; Choi, YJ; Han, DC; Hwang, SJ; Seng, WK; Teong, CC, 2005) |
| "Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension." | 2.69 | Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. ( Gehr, TW; Halstenson, CE; Keane, WF; Sica, DA, 2000) |
| "The current case indicates that late recurrences of scleroderma renal crisis are possible in renal transplant recipients and that angiotensin-converting enzyme inhibitors, rather than angiotensin II receptor blockers, may be the superior drugs for such patients." | 1.33 | Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. ( Cheung, WY; Gibson, IW; Jeffery, J; Karpinski, M; Rush, D, 2005) |
| "Renal hypertension was induced in Wistar strain male albino rats weighing 200-250 g by following the method of Goldblatt." | 1.32 | Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats. ( Ramanathan, M; Srinivasan, J; Suresh, B, 2003) |
| "Losartan treatment significantly prevented all these changes except STZ-induced hypoinsulinemia." | 1.32 | Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction. ( Goyal, RK; Murali, B; Umrani, DN, 2003) |
| " Bioavailability of TA-606 was 11 times higher than that of 606A in Sprague-Dawley rats, with consistent hypotensive potencies in spontaneously hypertensive rats (SHRs)." | 1.30 | Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. ( Hashimoto, Y; Hayashida, K; Kaji, H; Kurosawa, Y; Minami, K; Murata, S; Narita, H; Ohashi, R, 1998) |
| "In furosemide-treated dogs, orally given SK-1080 produced a dose-dependent and long-lasting (>8 h) antihypertensive effect with a rapid onset of action (time to Emax, 1-1." | 1.30 | In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. ( Kwon, KJ; Lee, BH; Seo, HW; Shin, HS; Yoo, SE, 1999) |
| "Losartan is a prodrug type Angiotensin II (Ang II) AT1-receptor antagonist whose efficacy depends on the oxidase activity of individuals." | 1.30 | Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension. ( Hashimoto, Y; Minami, K; Narita, H; Ohashi, R, 1999) |
| " In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril." | 1.29 | Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. ( Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994) |
| " In spontaneously hypertensive rats (SHR), repeated daily oral dosing of XR510, losartan, and enalapril at 30 mg/kg/day decreased BP similarly." | 1.29 | Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. ( Bernard, R; Crain, EJ; McCall, DE; Quan, ML; Saye, JM; Smith, RD; Watson, CA; Wexler, RR; Wong, PC; Zaspel, AM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (34.44) | 18.2507 |
| 2000's | 47 (52.22) | 29.6817 |
| 2010's | 11 (12.22) | 24.3611 |
| 2020's | 1 (1.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sircar, I | 1 |
| Hodges, JC | 1 |
| Quin, J | 1 |
| Bunker, AM | 1 |
| Winters, RT | 1 |
| Edmunds, JJ | 1 |
| Kostlan, CR | 1 |
| Connolly, C | 1 |
| Kesten, SJ | 1 |
| Hamby, JM | 1 |
| Bradbury, RH | 1 |
| Allott, CP | 1 |
| Dennis, M | 1 |
| Girdwood, JA | 1 |
| Kenny, PW | 1 |
| Major, JS | 1 |
| Oldham, AA | 1 |
| Ratcliffe, AH | 1 |
| Rivett, JE | 1 |
| Roberts, DA | 1 |
| Costantino, VV | 1 |
| Gil Lorenzo, AF | 1 |
| Bocanegra, V | 1 |
| Vallés, PG | 1 |
| Kim, JY | 1 |
| Son, JW | 1 |
| Park, S | 1 |
| Yoo, TH | 1 |
| Kim, YJ | 1 |
| Ryu, DR | 1 |
| Chin, HJ | 1 |
| Abdel-Zaher, AO | 1 |
| Farghaly, HSM | 1 |
| El-Refaiy, AEM | 1 |
| Abd-Eldayem, AM | 1 |
| Ávila, VF | 1 |
| Foresto-Neto, O | 1 |
| Arias, SCA | 1 |
| Faustino, VD | 1 |
| Malheiros, DMAC | 1 |
| Camara, NOS | 1 |
| Zatz, R | 3 |
| Fujihara, CK | 3 |
| Gao, S | 2 |
| Park, BM | 1 |
| Cha, SA | 1 |
| Park, WH | 2 |
| Park, BH | 1 |
| Kim, SH | 2 |
| Zhu, J | 1 |
| Zhang, Y | 1 |
| Yang, C | 1 |
| Wu, H | 1 |
| Liang, Y | 1 |
| Zheng, Y | 1 |
| Bai, Q | 1 |
| Zhuang, Z | 1 |
| A, L | 1 |
| Zheng, D | 1 |
| Wang, Y | 1 |
| Hayashi, M | 3 |
| Uchida, S | 3 |
| Kawamura, T | 3 |
| Kuwahara, M | 3 |
| Nangaku, M | 1 |
| Iino, Y | 3 |
| Donner, KM | 1 |
| Hiltunen, TP | 1 |
| Suonsyrjä, T | 1 |
| Hannila-Handelberg, T | 1 |
| Tikkanen, I | 1 |
| Antikainen, M | 1 |
| Hirvonen, A | 1 |
| Kontula, K | 1 |
| Polizio, AH | 1 |
| Gorzalczany, SB | 1 |
| Tomaro, ML | 1 |
| Oh, YB | 1 |
| Shah, A | 1 |
| Kim, JH | 1 |
| Persson, F | 1 |
| Lewis, JB | 1 |
| Lewis, EJ | 2 |
| Rossing, P | 3 |
| Hollenberg, NK | 1 |
| Parving, HH | 3 |
| Vaněčková, I | 1 |
| Kujal, P | 1 |
| Husková, Z | 1 |
| Vaňourková, Z | 1 |
| Vernerová, Z | 1 |
| Certíková Chábová, V | 1 |
| Skaroupková, P | 1 |
| Kramer, HJ | 1 |
| Tesař, V | 1 |
| Červenka, L | 1 |
| Al-Abadi, E | 1 |
| Milford, DV | 1 |
| Smith, M | 1 |
| Zhou, XJ | 1 |
| Vaziri, ND | 1 |
| Zhang, J | 2 |
| Wang, HW | 1 |
| Wang, XQ | 1 |
| Bertram, D | 1 |
| Blanc-Brunat, N | 1 |
| Sassard, J | 1 |
| Lo, M | 1 |
| Kucharewicz, I | 1 |
| Pawlak, R | 2 |
| Matys, T | 1 |
| Pawlak, D | 1 |
| Buczko, W | 2 |
| Zhou, QL | 1 |
| Deng, SL | 1 |
| Yang, JH | 1 |
| Eberhard, R | 1 |
| Dikow, R | 1 |
| Herman, WH | 1 |
| Shahinfar, S | 3 |
| Carides, GW | 3 |
| Dasbach, EJ | 1 |
| Gerth, WC | 1 |
| Alexander, CM | 1 |
| Cook, JR | 1 |
| Keane, WF | 2 |
| Brenner, BM | 2 |
| Srinivasan, J | 1 |
| Suresh, B | 1 |
| Ramanathan, M | 1 |
| Murali, B | 1 |
| Umrani, DN | 1 |
| Goyal, RK | 1 |
| Bautista, R | 1 |
| Manning, R | 1 |
| Martinez, F | 1 |
| Avila-Casado, Mdel C | 1 |
| Soto, V | 1 |
| Medina, A | 1 |
| Escalante, B | 1 |
| Shiigai, T | 2 |
| Tomino, Y | 2 |
| Yamada, K | 2 |
| Kitajima, T | 2 |
| Ideura, T | 2 |
| Koyama, A | 2 |
| Sugisaki, T | 2 |
| Suzuki, H | 3 |
| Umemura, S | 2 |
| Kawaguchi, Y | 1 |
| Yamazaki, T | 2 |
| Racasan, S | 1 |
| Hahnel, B | 1 |
| van der Giezen, DM | 1 |
| Blezer, EL | 1 |
| Goldschmeding, R | 1 |
| Braam, B | 1 |
| Kriz, W | 1 |
| Koomans, HA | 1 |
| Joles, JA | 1 |
| Soto, K | 1 |
| Gómez-Garre, D | 1 |
| Largo, R | 1 |
| Gallego-Delgado, J | 1 |
| Tejera, N | 1 |
| Catalán, MP | 1 |
| Ortiz, A | 1 |
| Plaza, JJ | 1 |
| Alonso, C | 1 |
| Egido, J | 1 |
| Høieggen, A | 1 |
| Alderman, MH | 1 |
| Kjeldsen, SE | 1 |
| Julius, S | 1 |
| Devereux, RB | 1 |
| De Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Chen, C | 1 |
| Dahlöf, B | 1 |
| Kanno, Y | 1 |
| Kawaguchii, Y | 1 |
| Gonçalves, AR | 1 |
| Mattar, AL | 1 |
| Malheiros, DM | 2 |
| Noronha, Ide L | 1 |
| de Nucci, G | 1 |
| Richer-Giudicelli, C | 1 |
| Domergue, V | 1 |
| Gonzalez, MF | 1 |
| Messadi, E | 1 |
| Azizi, M | 1 |
| Giudicelli, JF | 1 |
| Ménard, J | 1 |
| Nazir, FS | 1 |
| Overell, JR | 1 |
| Bolster, A | 1 |
| Hilditch, TE | 1 |
| Reid, JL | 1 |
| Lees, KR | 1 |
| Okigaki, M | 1 |
| Iwasaka, T | 1 |
| Mathur, S | 1 |
| Brown, CA | 1 |
| Dietrich, UM | 1 |
| Munday, JS | 1 |
| Newell, MA | 1 |
| Sheldon, SE | 1 |
| Cartier, LM | 1 |
| Brown, SA | 1 |
| Daskalopoulou, SS | 1 |
| Athyros, VG | 1 |
| Elisaf, M | 1 |
| Mikhailidis, D | 1 |
| Remuzzi, G | 1 |
| Ruggenenti, P | 1 |
| Perna, A | 1 |
| Dimitrov, BD | 1 |
| de Zeeuw, D | 4 |
| Hille, DA | 1 |
| Scaglione, R | 1 |
| Argano, C | 1 |
| Corrao, S | 1 |
| Di Chiara, T | 1 |
| Licata, A | 1 |
| Licata, G | 1 |
| Laverman, GD | 1 |
| Andersen, S | 2 |
| Navis, G | 1 |
| Cheung, WY | 1 |
| Gibson, IW | 1 |
| Rush, D | 1 |
| Jeffery, J | 1 |
| Karpinski, M | 1 |
| Lee, TM | 1 |
| Lin, MS | 1 |
| Tsai, CH | 1 |
| Chang, NC | 1 |
| Seng, WK | 1 |
| Hwang, SJ | 1 |
| Han, DC | 1 |
| Teong, CC | 1 |
| Chan, J | 1 |
| Burke, TA | 1 |
| Choi, YJ | 1 |
| Ferrario, CM | 2 |
| Jessup, J | 1 |
| Gallagher, PE | 2 |
| Averill, DB | 2 |
| Brosnihan, KB | 2 |
| Ann Tallant, E | 1 |
| Smith, RD | 3 |
| Chappell, MC | 2 |
| Jessup, JA | 1 |
| Tallant, EA | 1 |
| Hou, FF | 1 |
| Xie, D | 1 |
| Zhang, X | 1 |
| Chen, PY | 1 |
| Zhang, WR | 1 |
| Liang, M | 1 |
| Guo, ZJ | 1 |
| Jiang, JP | 1 |
| Liu, F | 1 |
| Brezniceanu, ML | 1 |
| Wei, CC | 1 |
| Chénier, I | 1 |
| Sachetelli, S | 1 |
| Zhang, SL | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Chan, JS | 1 |
| Baumann, M | 1 |
| Bartholome, R | 1 |
| Peutz-Kootstra, CJ | 1 |
| Smits, JF | 1 |
| Struijker-Boudier, HA | 1 |
| Machado, FG | 1 |
| Poppi, EP | 1 |
| Fanelli, C | 1 |
| Westhoff, JH | 1 |
| Hilgers, KF | 1 |
| Steinbach, MP | 1 |
| Hartner, A | 1 |
| Klanke, B | 1 |
| Amann, K | 1 |
| Melk, A | 1 |
| Niederberger, M | 1 |
| Aubert, JF | 1 |
| Nussberger, J | 1 |
| Brunner, HR | 1 |
| Waeber, B | 1 |
| Gansevoort, RT | 2 |
| de Jong, PE | 2 |
| Lacour, C | 1 |
| Canals, F | 1 |
| Galindo, G | 1 |
| Cazaubon, C | 1 |
| Segondy, D | 1 |
| Nisato, D | 1 |
| Nagura, J | 1 |
| Yasuda, S | 1 |
| Fujishima, K | 1 |
| Yamamoto, M | 1 |
| Hui, C | 1 |
| Kawano, K | 1 |
| Katano, K | 1 |
| Ogino, H | 1 |
| Hachisu, M | 1 |
| Konno, F | 1 |
| Basso, N | 1 |
| Kurnjek, ML | 1 |
| Ruiz, P | 1 |
| Cannata, MA | 1 |
| Baboolal, K | 1 |
| Meyer, TW | 2 |
| Nicolaï, E | 1 |
| Curé, G | 1 |
| Goyard, J | 1 |
| Kirchner, M | 1 |
| Teulon, JM | 1 |
| Versigny, A | 1 |
| Cazes, M | 1 |
| Virone-Oddos, A | 1 |
| Caussade, F | 1 |
| Cloarec, A | 1 |
| Redfield, A | 1 |
| Wong, PC | 4 |
| Duncia, JV | 2 |
| Santella, JB | 1 |
| Wexler, RR | 3 |
| Timmermans, PB | 3 |
| Chiu, AT | 2 |
| Van Meel, JC | 1 |
| Van Zwieten, PA | 1 |
| Kanagy, NL | 1 |
| Fink, GD | 1 |
| Quan, ML | 1 |
| Saye, JM | 1 |
| Bernard, R | 1 |
| Crain, EJ | 1 |
| McCall, DE | 1 |
| Watson, CA | 1 |
| Zaspel, AM | 1 |
| Caskey, FJ | 1 |
| Thacker, EJ | 1 |
| Johnston, PA | 1 |
| Barnes, JN | 1 |
| Shibasaki, M | 1 |
| Fujimori, A | 1 |
| Kusayama, T | 1 |
| Tokioka, T | 1 |
| Satoh, Y | 1 |
| Okazaki, T | 1 |
| Uchida, W | 1 |
| Inagaki, O | 1 |
| Yanagisawa, I | 1 |
| Hashimoto, Y | 2 |
| Ohashi, R | 2 |
| Kurosawa, Y | 1 |
| Minami, K | 2 |
| Kaji, H | 1 |
| Hayashida, K | 1 |
| Narita, H | 2 |
| Murata, S | 1 |
| Birck, R | 1 |
| Keim, V | 1 |
| Fiedler, F | 1 |
| van der Woude, FJ | 1 |
| Rohmeiss, P | 1 |
| Fernández-Andrade, C | 1 |
| Russo, D | 1 |
| Iversen, B | 1 |
| Zucchelli, P | 1 |
| Aranda, P | 1 |
| Guerra, L | 1 |
| Casado, S | 1 |
| del Castillo, D | 1 |
| Campistol, JM | 1 |
| Guirado, L | 1 |
| Capdevilla, L | 1 |
| Martínez, JG | 1 |
| Pereira, P | 1 |
| Bravo, J | 1 |
| Pérez, R | 1 |
| Saracho, R | 1 |
| Martin-Malo, A | 1 |
| Martinez, I | 1 |
| Aljama, P | 1 |
| Montenegro, J | 1 |
| Lee, BH | 2 |
| Seo, HW | 2 |
| Kwon, KJ | 1 |
| Yoo, SE | 2 |
| Shin, HS | 2 |
| Chabielska, E | 1 |
| Wollny, T | 1 |
| Rółkowski, R | 1 |
| Kutyrina, IM | 1 |
| Tareeva, IE | 1 |
| Nosikov, VV | 1 |
| Kamyshova, ES | 1 |
| Gorashko, NM | 1 |
| Chistiakov, DA | 1 |
| Okonova, EB | 1 |
| Troepol'skaia, OV | 1 |
| Cha, YJ | 1 |
| Pearson, VE | 1 |
| Wang, CT | 1 |
| Zou, LX | 1 |
| Navar, LG | 1 |
| Lee, SH | 1 |
| Jung, YS | 1 |
| Tarnow, L | 1 |
| Hansen, BV | 1 |
| Parker, SB | 1 |
| Dobrian, AD | 1 |
| Wade, SS | 1 |
| Prewitt, RL | 1 |
| Adzhienko, LM | 1 |
| Lottermoser, K | 1 |
| Hertfelder, HJ | 1 |
| Vetter, H | 1 |
| Düsing, R | 1 |
| Sica, DA | 1 |
| Halstenson, CE | 1 |
| Gehr, TW | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Sorooshian, M | 1 |
| Olson, JL | 1 |
| Farah, VM | 1 |
| Moreira, ED | 1 |
| Ushizima, M | 1 |
| Cestari, IA | 1 |
| Irigoyen, MC | 1 |
| Krieger, EM | 1 |
| Jerums, G | 1 |
| Cooper, ME | 1 |
| Gilbert, RE | 1 |
| Atkins, RC | 1 |
| Ye, S | 1 |
| Zhong, H | 1 |
| Duong, VN | 1 |
| Campese, VM | 1 |
| Christ, DD | 1 |
| Wood, JM | 1 |
| Mah, SC | 1 |
| Schnell, C | 1 |
| Price, WA | 1 |
| Carini, DJ | 1 |
| Johnson, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02620306] | Phase 3 | 351 participants (Actual) | Interventional | 2016-02-11 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately[NCT05090449] | Phase 1 | 36 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease[NCT01087749] | Phase 1 | 24 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for losartan and Hypertension, Renal
| Article | Year |
|---|---|
Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.
Topics: Animals; Epithelial-Mesenchymal Transition; HSP70 Heat-Shock Proteins; Humans; Hypertension, Renal; | 2021 |
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
[Diagnosis of and therapy for renal hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel B | 2004 |
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2004 |
23 trials available for losartan and Hypertension, Renal
| Article | Year |
|---|---|
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials, Phase III | 2017 |
Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2015 |
CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.
Topics: Adult; Aldosterone; Amlodipine; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Bisoprolol; | 2009 |
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabe | 2011 |
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2003 |
Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2003 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Creatinine; End | 2004 |
Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Japan; Kidney Failur | 2004 |
The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cerebrovascular Ci | 2004 |
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2004 |
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Drug | 2005 |
Renoprotection with and without blood pressure reduction.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, Renal; Lo | 2005 |
Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Drug Interactions; Drug Resistance; Endothelin-1; Fe | 2005 |
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Cost-Benefit Analysi | 2005 |
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2007 |
Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Gl | 1994 |
Comparison of losartan and amlodipine in renally impaired hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium; Creatine; Fe | 1998 |
Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cyclosporine; Drug Interactions; Female; Humans; Hyp | 1998 |
Evaluation of the Losartan in Hemodialysis (ELHE) Study.
Topics: Acrylic Resins; Acrylonitrile; Adult; Aged; Aged, 80 and over; Anaphylaxis; Angiotensin Receptor Ant | 1998 |
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Fibrinolytic function in diuretic-induced volume depletion.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Blood Volume; Diuretics; Drug Therapy, Combination; | 2000 |
Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.
Topics: Adult; Aldosterone; Antihypertensive Agents; Area Under Curve; Blood Pressure; Female; Half-Life; Hu | 2000 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
63 other studies available for losartan and Hypertension, Renal
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Disease Models, Animal; GABA Antagonists; gamma-Am | 1993 |
New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives.
Topics: Adrenal Glands; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; | 1993 |
Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Cardiovascular Agents; Ginkgo biloba; Glutathio | 2018 |
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Female; G | 2019 |
Angiotensin AT2 receptor agonist stimulates high stretch induced- ANP secretion via PI3K/NO/sGC/PKG/pathway.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Atrial Pressure; Cyclic GMP-Dependent Protein Ki | 2013 |
Protective effect of 3-n-butylphthalide against hypertensive nephropathy in spontaneously hypertensive rats.
Topics: Albumins; Animals; Antihypertensive Agents; Benzofurans; Blood Pressure; Blood Urea Nitrogen; Drugs, | 2015 |
Up-regulation of intrarenal renin-agiotensin system contributes to renal damage in high-salt induced hypertension rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Diet; Hypertensio | 2014 |
Lowering arterial pressure delays the oxidative stress generation in a renal experimental model of hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Disease Models, Animal; Heme Oxyg | 2009 |
Endogenous angiotensin II suppresses stretch-induced ANP secretion via AT1 receptor pathway.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Blood Pressure | 2011 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasent | 2012 |
A patient with bilateral facial palsy associated with hypertension and chickenpox: learning points.
Topics: Acyclovir; Antihypertensive Agents; Antiviral Agents; Chickenpox; Child; Cooperative Behavior; Diagn | 2010 |
Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Hypertension, | 2002 |
Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; | 2002 |
Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2002 |
Angiotensin II receptor blockade in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2003 |
[Effects of angiotension II receptor antagonist on the level ET and NO in the patients with renal hypertension and protection of renal function].
Topics: Adult; Angiotensin Receptor Antagonists; Endothelin-1; Female; Glomerulonephritis; Humans; Hypertens | 2001 |
Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Anx | 2003 |
Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Experimental; Diabe | 2003 |
Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
Temporary losartan or captopril in young SHR induces malignant hypertension despite initial normotension.
Topics: Animals; Animals, Suckling; Antihypertensive Agents; Blood Pressure; Captopril; Female; Hypertension | 2004 |
Tight blood pressure control decreases apoptosis during renal damage.
Topics: Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Division; Drug Therapy, Combinatio | 2004 |
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cyclooxyg | 2004 |
Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt.
Topics: Anesthesia; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressu | 2004 |
Evaluation of a technique of inducing hypertensive renal insufficiency in cats.
Topics: Amlodipine; Analysis of Variance; Animals; Blood Pressure; Blood Pressure Determination; Cat Disease | 2004 |
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension, Renal; Losartan; Uric Acid | 2004 |
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2005 |
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2005 |
Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagon | 2006 |
Overexpression of angiotensinogen increases tubular apoptosis in diabetes.
Topics: Albuminuria; Angiotensinogen; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protei | 2008 |
Sustained tubulo-interstitial protection in SHRs by transient losartan treatment: an effect of decelerated aging?
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Cycle; Cell Division; Hyperplasia; Hyp | 2008 |
AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Female; Hypertension, Rena | 2008 |
Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Ag | 2008 |
Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood | 1995 |
Losartan in patients with renal insufficiency.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 1995 |
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; | 1994 |
Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; | 1995 |
Effect of EXP 3174 on blood pressure of normoreninemic renal hypertensive rats.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Hypertension, Renal; Im | 1995 |
The effect of acute angiotensin II blockade on renal function in rats with reduced renal mass.
Topics: Albuminuria; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Hypertension, Renal; Imida | 1994 |
Synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole derivatives.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1994 |
EXP597, a nonpeptide angiotensin II receptor antagonist with high affinities for the angiotensin AT1 and AT2 receptor subtypes.
Topics: Administration, Oral; Adrenal Cortex; Adrenal Medulla; Angiotensin Receptor Antagonists; Animals; Ao | 1994 |
Antihypertensive activity of the novel, nonpeptide angiotensin II receptor antagonists BIBS 39 and BIBS 222 in conscious renal hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1993 |
Losartan prevents salt-induced hypertension in reduced renal mass rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1993 |
Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Administration, Oral; Adrenal Glands; Angiotensin Receptor | 1995 |
Failure of losartan to control blood pressure in scleroderma renal crisis.
Topics: Acute Kidney Injury; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 1997 |
Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Azoles; Biphenyl | 1997 |
Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Availability; Blood P | 1998 |
Pancreatitis after losartan.
Topics: Acute Disease; Adult; Antihypertensive Agents; Diabetic Nephropathies; Female; Humans; Hypertension, | 1998 |
In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Ag | 1999 |
Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Platelets; Disease Models, Animal; Fibrinolytic Age | 1999 |
[Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
Topics: Adolescent; Adult; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 1999 |
Angioedema due to losartan.
Topics: Acute Kidney Injury; Angioedema; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Losar | 1999 |
Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats.
Topics: Analysis of Variance; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressur | 1997 |
Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; A | 1999 |
Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Dogs; Dose-Respo | 1999 |
AT(1) receptor inhibition does not reduce arterial wall hypertrophy or PDGF-A expression in renal hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Arteries; Blood Pressure; Bromodeoxyurid | 2000 |
[Cerebrovascular circulation during blockade of angiotensin receptors].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cerebrovascular | 2000 |
Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2000 |
Acute AT1 receptor blockade does not improve the depressed baroreflex in rats with chronic renal hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Brad | 2000 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2001 |
Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain; Central Nervous System; Cerebral Ventricles | 2002 |
Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Decer | 1992 |
Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Analysis of Variance; Angiotensin II; Angiotensin-Convertin | 1990 |
Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Azoles; Biphenyl Compounds; Guinea Pigs; Hy | 1990 |